Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Clinical trial NCT02454933 · COMPLETED

Trial details

NCT number: NCT02454933
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Start date: 2015-07-15
Primary completion: 2017-08-21
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.